JAK–STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review

IH Huang, WH Chung, PC Wu, CB Chen - Frontiers in immunology, 2022 - frontiersin.org
Atopic dermatitis (AD) is a chronic, inflammatory, pruritic form of dermatosis with
heterogeneous manifestations that can substantially affect patients' quality of life. AD has a …

Protein kinases: drug targets for immunological disorders

L Castelo-Soccio, H Kim, M Gadina… - Nature Reviews …, 2023 - nature.com
Protein kinases play a major role in cellular activation processes, including signal
transduction by diverse immunoreceptors. Given their roles in cell growth and death and in …

Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study

M Heiblig, MA Ferrada, MT Koster… - Blood, The Journal …, 2022 - ashpublications.org
VEXAS syndrome (vacuoles in myeloid progenitors, E1 ubiquitin activating enzyme, X-
linked, autoinflammatory manifestations and somatic) is an autoinflammatory condition …

JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition

Y Luo, M Alexander, M Gadina, JJ O'Shea… - Journal of Allergy and …, 2021 - Elsevier
Since its discovery, the Janus kinase-signal transduction and activation of transcription (JAK-
STAT) pathway has become recognized as a central mediator of widespread and varied …

The safety of JAK-1 inhibitors

B Clarke, M Yates, M Adas, K Bechman… - Rheumatology, 2021 - academic.oup.com
As efficacy and safety data emerge, differences between JAK inhibitor subclasses are
appearing. JAK1 selective drugs, upadacitinib and filgotinib, have broadly come with the …

Janus kinase 1 inhibitor INCB054707 for patients with moderate‐to‐severe hidradenitis suppurativa: results from two phase II studies

A Alavi, I Hamzavi, K Brown, LL Santos… - British Journal of …, 2022 - academic.oup.com
Background Janus kinase (JAK)‐mediated cytokine signalling contributes to local and
systemic inflammation in hidradenitis suppurativa (HS). Objectives To describe the safety …

JAK inhibitors for asthma

SN Georas, P Donohue, M Connolly… - Journal of allergy and …, 2021 - Elsevier
Asthma is an inflammatory disease of the airways characterized by intermittent episodes of
wheezing, chest tightness, and cough. Many of the inflammatory pathways implicated in …

Association of risk of incident venous thromboembolism with atopic dermatitis and treatment with Janus kinase inhibitors: a systematic review and meta-analysis

TL Chen, LL Lee, HK Huang, LY Chen… - JAMA …, 2022 - jamanetwork.com
Importance The risk of venous thromboembolism (VTE) among patients with atopic
dermatitis (AD), especially when receiving treatment with Janus kinase (JAK) inhibitors, is …

JAK‐inhibitors in dermatology–small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects

B Klein, R Treudler, JC Simon - JDDG: Journal der Deutschen …, 2022 - Wiley Online Library
Numerous chronic inflammatory skin diseases are associated with the release of
proinflammatory cytokines, which act via the intracellular JAK‐STAT pathway. JAK inhibitors …

JAK inhibitors: A new dawn for oral therapies in inflammatory bowel diseases

C Herrera-deGuise, X Serra-Ruiz, E Lastiri… - Frontiers in …, 2023 - frontiersin.org
Inflammatory bowel disease (IBD) is a chronic immune-mediated condition of the
gastrointestinal tract that requires chronic treatment and strict surveillance. Development of …